JAMA ophthalmology · 2021
Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.
Conference ProceedingsПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brodie Frank, Repka Michael, Burns Stephen Allan, Prakalapakorn S Grace, Morse Christie, Schuman Joel S, Duenas Michael R, Afshari Natalie, Pollack John S, Thorne Jennifer E, Vitale Albert, Sen H Nida, Myung David, Blumenkranz Mark S, Tu Elmer, Hammer Daniel X, Tarver Michelle, Cunningham Bradley, Kagemann Larry, Sadda SriniVas, Sarraf David, Jaffe Glenn J, Eydelman Malvina
Аннотация
In April 2019, the US Food and Drug Administration, in conjunction with 11 professional ophthalmic, vision science, and optometric societies, convened a forum on laser-based imaging. The forum brought together the Food and Drug Administration, clinicians, researchers, industry members, and other stakeholders to stimulate innovation and ensure that patients in the US are the first in the world to have access to high-quality, safe, and effective medical devices. This conference focused on the technology, clinical applications, regulatory issues, and reimbursement issues surrounding innovative ocular imaging modalities. Furthermore, the emerging role of artificial intelligence in ophthalmic imaging was reviewed. This article summarizes the presentations, discussion, and future directions.
Предметные рубрики MeSH
Artificial IntelligenceDiffusion of InnovationEyeEye DiseasesHumansImage Interpretation, Computer-AssistedLasersOphthalmoscopesOphthalmoscopyPatient SafetyPredictive Value of TestsRisk AssessmentRisk FactorsTechnology Assessment, BiomedicalTomography, Optical CoherenceUnited StatesUnited States Food and Drug Administration